Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.91 |
| ▸ | PGR | P06401 | 3/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.91 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | SHBG | P04278 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL7665 | 1.00 | HIF1A (0.91) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL3105442 | 0.99 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL2881419 | 0.99 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL28908729 | 0.96 | HIF1A (0.86) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL4697 | 0.96 | HIF1A (0.86) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL3999007 | 0.95 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL24900238 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL1688689 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL5699764 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL143923 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 946 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152705-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-05-15 | — | — | US | claimed |
| CN-119657043-A | Device and method for preparing hydrocortisone sodium succinate | 西安国康瑞金制药有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-117257742-B | Preparation method of hydrocortisone sodium succinate freeze-dried powder injection for injection | 烟台东诚北方制药有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119464390-A | Method for constructing human umbilical vein endothelial cell model of trans-mitochondria | 浙江大学 | 2025-02-18 | — | — | CN | claimed |
| CN-119265038-A | Vascularized tissue culture chip and construction method and application thereof | 武汉市中西医结合医院（武汉市第一医院） | 2025-01-07 | — | — | CN | claimed |
| EP-4463228-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | Sun Pharmaceutical Industries Limited (IN) | 2024-11-20 | — | — | EP | claimed |
| CN-118935929-A | Preparation method and device of hydrocortisone sodium succinate injection | 西安国康瑞金制药有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-117512012-A | Immortalized human scleral fibroblast and construction method thereof | 首都医科大学附属北京同仁医院 | 2024-02-06 | — | — | CN | claimed |
| CN-117257742-A | Preparation method of hydrocortisone sodium succinate freeze-dried powder injection for injection | 烟台东诚北方制药有限公司 | 2023-12-22 | — | — | CN | claimed |
| WO-2023135554-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2023-07-20 | — | — | WO | claimed |
| US-20050004098-A1 | Dispersible formulation of an anti-inflammatory agent | BRITTEN NANCY JEAN (US) | 2005-01-06 | — | — | US | claimed |
| US-20040235803-A1 | Dispersible formulation of an anti-inflammatory agent | PHARMACIA & UPJOHN COMPANY | 2004-11-25 | — | — | US | claimed |
| US-20040214753-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| WO-2004082719-A1 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004082588-A2 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-6324424-B1 | Reduction of skin irritation during electrotransport delivery | ALZA CORPORATION | 2001-11-27 | — | — | US | claimed |
| EP-0752898-B1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORP (US) | 1998-04-29 | — | — | EP | claimed |
| WO-1998012304-A1 | CULTURE SYSTEM FOR HEMATOPOIETIC STEM CELLS | MEDICAL RESEARCH COUNCIL (GB) | 1998-03-26 | — | — | WO | claimed |
| EP-0752898-A1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1997-01-15 | — | — | EP | claimed |
| WO-1995026782-A1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235803-A1 | Dispersible formulation of an anti-inflammatory agent | TNF, LTB4R2, LTA | NR3C1 1402/4885HIF1A 3813/4885HSD17B10 1600/4885 |
| US-20050004098-A1 | Dispersible formulation of an anti-inflammatory agent | TNF, IL6, IL1A | NR3C1 2938/4885HIF1A 3560/4885HSD17B10 1552/4885 |
| US-20040214753-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | OTC, AQP3, AQP1 | NR3C1 2612/4885HIF1A 3076/4885HSD17B10 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.